Research programme: serotonin 2C receptor agonists - Bristol-Myers Squibb

Drug Profile

Research programme: serotonin 2C receptor agonists - Bristol-Myers Squibb

Alternative Names: A 37215; IK 264; IX 065

Latest Information Update: 18 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 05 Apr 2005 This programme is still in active development - (229th American Chemical Society National Meeting (229th-ACS-2005))
  • 22 Oct 2002 A preclinical study has been added to the Obesity pharmacodynamics section
  • 23 Apr 2001 Preclinical development for Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top